Bind Therapeutics Inc (BIND) 6.06 $BIND
BIND Therapeutics Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
Business Wire - Tue Feb 10, 10:33AM CST
BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced the closing of its previously announced public offering of 3,739,130 units at the public offering price of $5.75 per unit. Each unit consisted of one share of common stock and six-tenths (0.6) of a warrant to purchase one share of common stock with an exercise price of $6.60 per share.
BIND: 6.06 (+0.21)
Nasdaq stocks posting largest percentage decreases
AP - Thu Feb 05, 12:21PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
SPLS: 16.86 (-0.22), PPSI: 9.09 (-0.26), GEOS: 19.15 (+0.02), MYGN: 34.03 (+0.40), ADEP: 6.93 (-0.30), PACB: 6.96 (-0.06), MTRX: 19.92 (+0.77), LAYN: 7.93 (+0.22), LFUS: 98.58 (+0.50), ACHN: 10.89 (-0.20), BNFT: 21.08 (+0.84), AIRT: 19.45 (+0.39), BIND: 6.06 (+0.21), POWL: 33.41 (+0.39), PLNR: 6.63 (-0.07)
Bind Therapeutics prices offering
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 8:43AM CST
BIND: 6.06 (+0.21)
BIND Therapeutics Prices Public Offering of Common Stock and Warrants to Purchase Common Stock
Business Wire - Thu Feb 05, 7:59AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced the pricing of its underwritten public offering of 3,739,130 units at the public offering price of $5.75 per unit. Each unit consists of one share of common stock and six-tenths (0.6) of a warrant to purchase one share of common stock with an exercise price of $6.60 per share. All units in the offering are to be sold by BIND. The gross proceeds to BIND from this offering are expected to be approximately $21.5 million, not including any future proceeds from the exercise of the warrants.
BIND: 6.06 (+0.21)
Bind Therapeutics initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 4:05PM CST
BIND: 6.06 (+0.21)
BIND Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
Business Wire - Wed Feb 04, 3:32PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that it is commencing an underwritten public offering of units consisting of shares of BIND's common stock and warrants to purchase shares of BIND's common stock. All of the units in the offering are to be sold by BIND.
BIND: 6.06 (+0.21)
BIND Therapeutics amends and increases existing USD3m credit facility with Hercules Technology III
M2 - Mon Jan 26, 4:16AM CST
Nanomedicine company BIND Therapeutics (BIND) reported on Friday an amendment to its existing credit facility with Hercules Technology III, L.P., an affiliate of Hercules Technology Growth Capital (NYSE:HTCG).
HTGC: 15.49 (+0.04), BIND: 6.06 (+0.21)
BIND Therapeutics Amends Credit Facility from Hercules Technology III, L.P. to Accelerate Accurin Pipeline Growth
Business Wire - Fri Jan 23, 4:00PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that it has entered into an amendment of its existing credit facility from Hercules Technology III, L.P., an affiliate of Hercules Technology Growth Capital (NYSE: HTCG). Under the amendment, the company borrowed an additional $15 million in growth capital, less the repayment of the outstanding balance on BIND's existing term loan facility of approximately $3 million.
HTGC: 15.49 (+0.04), BIND: 6.06 (+0.21)
BIND Therapeutics Co-Founder Publishes Nanotechnology Article in the Journal of the American Medical Association
Business Wire - Thu Jan 22, 7:00AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced the publication of an article in the Journal of the American Medical Association (JAMA) co-authored by Robert S. Langer, Sc.D, David H. Koch Institute Professor, Massachusetts Institute of Technology, co-founder and member of the Board of Directors of BIND and one of seven individuals to have received both the United States National Medal of Science and the United States National Medal of Technology and Innovation. In the article, titled "Science and Medicine: Nanotechnology," Dr. Langer provides his vision of therapeutic improvements that may be possible with drug-containing nanoparticles, including the ability to provide potent doses of cancer-killing agents to cancer cells while reducing off-target toxicities.
BIND: 6.06 (+0.21)
Securities Lending Notable Names: JCP, AMBA
Interactive Brokers - at Seeking Alpha - Tue Jan 13, 2:32AM CST
Strong sales guidance gave some life to struggling department store operator, J.C. Penney Co., Inc. (NYSE: JCP ) last week following a prolonged period of negative news. The stock soared approximately 17% on Tuesday of last week after the company...
AMBA: 50.71 (-4.46), GPRO: 45.27 (-0.02), EDAP: 3.55 (+0.13), LNCO: 12.30 (+0.28), IMRS: 1.04 (-0.03), GALT: 3.84 (+0.16), JCP: 8.05 (+0.14), MOC: 2.24 (+0.02), BIND: 6.06 (+0.21), LINE: 12.94 (+0.40), JOB: 0.79 (+0.01), BCLI: 3.86 (-0.02), NDRM: 10.76 (+0.22)
BIND Rises To Validate Its Accurin Program (Again)
Clinically Sound Investor - at Seeking Alpha - Fri Jan 09, 6:55AM CST
BIND: 6.06 (+0.21)
Trending Now: New Research on Aeropostale, Impax, Facebook, TripAdvisor and BIND Therapeutics
PR Newswire - Fri Jan 09, 6:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Aeropostale (NYSE: ARO), Impax (NASDAQ: IPXL), Facebook (NASDAQ: FB), TripAdvisor (NASDAQ: TRIP), and BIND Therapeutics (NASDAQ: BIND). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
IPXL: 39.51 (+0.69), FB: 75.74 (-0.49), TRIP: 84.81 (+2.41), BIND: 6.06 (+0.21), ARO: 3.63 (+0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 11:47AM CST
ELOS: 10.16 (+0.07), MBII: 3.88 (+0.33), PDFS: 18.31 (+0.04), CASM: 1.36 (-0.01), PHMD: 1.68 (+0.04), EPRS: 7.67 (+0.67), BIND: 6.06 (+0.21), JOB: 0.79 (+0.01), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), ARO: 3.63 (+0.04), PODD: 32.00 (-0.07), AOI: 1.05 (+0.03), BWEN: 5.48 (+0.15), NBIX: 37.22 (+0.27), VLCCF: 4.15 (-0.06), NEFF: 10.43 (-0.04), PSTR: 4.63 (+0.14), INFI: 15.13 (+0.55), APOL: 25.97 (+0.33)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST
NRX: 6.67 (-0.14), BIND: 6.06 (+0.21), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), SIG: 120.19 (+0.36), PBR: 6.98 (+0.44), NBIX: 37.22 (+0.27), PIR: 12.52 (+0.17), VLCCF: 4.15 (-0.06), CONN: 24.69 (-0.07), CYTR: 2.96 (+0.23), PLX: 1.84 (-0.04), MEET: 1.78 (+0.02), INFI: 15.13 (+0.55), CYRN: 2.83 (+0.23), APOL: 25.97 (+0.33), CJJD: 2.59 (-0.01), CRK: 6.09 (+0.46), FOLD: 8.36 (-0.11), GST: 2.89 (unch)
Bind Therapeutics up big premarket on lead product update and strategic outlook
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 6:50AM CST
BIND: 6.06 (+0.21)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 4:35PM CST
MPW: 14.64 (+0.14), WDFC: 82.95 (+0.21), SU: 31.62 (+0.30), PODD: 32.00 (-0.07), RECN: 17.46 (-0.15), RARE: 54.10 (+0.12), AFSI: 55.60 (-0.89), AGU: 108.58 (+1.60), ALXN: 182.29 (+6.02), BIND: 6.06 (+0.21)
BIND Therapeutics Provides Clinical Update for BIND-014 and 2015 Strategic Overview
Business Wire - Wed Jan 07, 3:00PM CST
--- Initiating Phase 2 clinical trials in a broader array of tumors with a rationale for BIND-014 activity, including cholangiocarcinoma, cervical cancer, bladder cancer and head and neck cancer -
BIND: 6.06 (+0.21)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.83 (+0.22), BIB: 141.30 (+2.39), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), BIND: 6.06 (+0.21), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), ONTY: 1.57 (unch), ECYT: 5.26 (-0.02), BIS: 39.67 (-0.75), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), ARIA: 7.35 (+0.45), IRY: 49.63 (+0.34), IXJ: 104.21 (+0.61), FPRX: 24.63 (+0.63)
BIND Therapeutics to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Wed Nov 26, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference in New York on Thursday, December 11, 2014 at 3:55 p.m. EST.
BIND: 6.06 (+0.21)
BIND Therapeutics Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
Business Wire - Tue Feb 10, 10:33AM CST
BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced the closing of its previously announced public offering of 3,739,130 units at the public offering price of $5.75 per unit. Each unit consisted of one share of common stock and six-tenths (0.6) of a warrant to purchase one share of common stock with an exercise price of $6.60 per share.
BIND: 6.06 (+0.21)
Nasdaq stocks posting largest percentage decreases
AP - Thu Feb 05, 12:21PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
SPLS: 16.86 (-0.22), PPSI: 9.09 (-0.26), GEOS: 19.15 (+0.02), MYGN: 34.03 (+0.40), ADEP: 6.93 (-0.30), PACB: 6.96 (-0.06), MTRX: 19.92 (+0.77), LAYN: 7.93 (+0.22), LFUS: 98.58 (+0.50), ACHN: 10.89 (-0.20), BNFT: 21.08 (+0.84), AIRT: 19.45 (+0.39), BIND: 6.06 (+0.21), POWL: 33.41 (+0.39), PLNR: 6.63 (-0.07)
Bind Therapeutics prices offering
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 8:43AM CST
BIND: 6.06 (+0.21)
BIND Therapeutics Prices Public Offering of Common Stock and Warrants to Purchase Common Stock
Business Wire - Thu Feb 05, 7:59AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced the pricing of its underwritten public offering of 3,739,130 units at the public offering price of $5.75 per unit. Each unit consists of one share of common stock and six-tenths (0.6) of a warrant to purchase one share of common stock with an exercise price of $6.60 per share. All units in the offering are to be sold by BIND. The gross proceeds to BIND from this offering are expected to be approximately $21.5 million, not including any future proceeds from the exercise of the warrants.
BIND: 6.06 (+0.21)
Bind Therapeutics initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 4:05PM CST
BIND: 6.06 (+0.21)
BIND Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
Business Wire - Wed Feb 04, 3:32PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that it is commencing an underwritten public offering of units consisting of shares of BIND's common stock and warrants to purchase shares of BIND's common stock. All of the units in the offering are to be sold by BIND.
BIND: 6.06 (+0.21)
BIND Therapeutics amends and increases existing USD3m credit facility with Hercules Technology III
M2 - Mon Jan 26, 4:16AM CST
Nanomedicine company BIND Therapeutics (BIND) reported on Friday an amendment to its existing credit facility with Hercules Technology III, L.P., an affiliate of Hercules Technology Growth Capital (NYSE:HTCG).
HTGC: 15.49 (+0.04), BIND: 6.06 (+0.21)
BIND Therapeutics Amends Credit Facility from Hercules Technology III, L.P. to Accelerate Accurin Pipeline Growth
Business Wire - Fri Jan 23, 4:00PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that it has entered into an amendment of its existing credit facility from Hercules Technology III, L.P., an affiliate of Hercules Technology Growth Capital (NYSE: HTCG). Under the amendment, the company borrowed an additional $15 million in growth capital, less the repayment of the outstanding balance on BIND's existing term loan facility of approximately $3 million.
HTGC: 15.49 (+0.04), BIND: 6.06 (+0.21)
BIND Therapeutics Co-Founder Publishes Nanotechnology Article in the Journal of the American Medical Association
Business Wire - Thu Jan 22, 7:00AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced the publication of an article in the Journal of the American Medical Association (JAMA) co-authored by Robert S. Langer, Sc.D, David H. Koch Institute Professor, Massachusetts Institute of Technology, co-founder and member of the Board of Directors of BIND and one of seven individuals to have received both the United States National Medal of Science and the United States National Medal of Technology and Innovation. In the article, titled "Science and Medicine: Nanotechnology," Dr. Langer provides his vision of therapeutic improvements that may be possible with drug-containing nanoparticles, including the ability to provide potent doses of cancer-killing agents to cancer cells while reducing off-target toxicities.
BIND: 6.06 (+0.21)
Securities Lending Notable Names: JCP, AMBA
Interactive Brokers - at Seeking Alpha - Tue Jan 13, 2:32AM CST
Strong sales guidance gave some life to struggling department store operator, J.C. Penney Co., Inc. (NYSE: JCP ) last week following a prolonged period of negative news. The stock soared approximately 17% on Tuesday of last week after the company...
AMBA: 50.71 (-4.46), GPRO: 45.27 (-0.02), EDAP: 3.55 (+0.13), LNCO: 12.30 (+0.28), IMRS: 1.04 (-0.03), GALT: 3.84 (+0.16), JCP: 8.05 (+0.14), MOC: 2.24 (+0.02), BIND: 6.06 (+0.21), LINE: 12.94 (+0.40), JOB: 0.79 (+0.01), BCLI: 3.86 (-0.02), NDRM: 10.76 (+0.22)
BIND Rises To Validate Its Accurin Program (Again)
Clinically Sound Investor - at Seeking Alpha - Fri Jan 09, 6:55AM CST
BIND: 6.06 (+0.21)
Trending Now: New Research on Aeropostale, Impax, Facebook, TripAdvisor and BIND Therapeutics
PR Newswire - Fri Jan 09, 6:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Aeropostale (NYSE: ARO), Impax (NASDAQ: IPXL), Facebook (NASDAQ: FB), TripAdvisor (NASDAQ: TRIP), and BIND Therapeutics (NASDAQ: BIND). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
IPXL: 39.51 (+0.69), FB: 75.74 (-0.49), TRIP: 84.81 (+2.41), BIND: 6.06 (+0.21), ARO: 3.63 (+0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 11:47AM CST
ELOS: 10.16 (+0.07), MBII: 3.88 (+0.33), PDFS: 18.31 (+0.04), CASM: 1.36 (-0.01), PHMD: 1.68 (+0.04), EPRS: 7.67 (+0.67), BIND: 6.06 (+0.21), JOB: 0.79 (+0.01), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), ARO: 3.63 (+0.04), PODD: 32.00 (-0.07), AOI: 1.05 (+0.03), BWEN: 5.48 (+0.15), NBIX: 37.22 (+0.27), VLCCF: 4.15 (-0.06), NEFF: 10.43 (-0.04), PSTR: 4.63 (+0.14), INFI: 15.13 (+0.55), APOL: 25.97 (+0.33)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST
NRX: 6.67 (-0.14), BIND: 6.06 (+0.21), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), SIG: 120.19 (+0.36), PBR: 6.98 (+0.44), NBIX: 37.22 (+0.27), PIR: 12.52 (+0.17), VLCCF: 4.15 (-0.06), CONN: 24.69 (-0.07), CYTR: 2.96 (+0.23), PLX: 1.84 (-0.04), MEET: 1.78 (+0.02), INFI: 15.13 (+0.55), CYRN: 2.83 (+0.23), APOL: 25.97 (+0.33), CJJD: 2.59 (-0.01), CRK: 6.09 (+0.46), FOLD: 8.36 (-0.11), GST: 2.89 (unch)
Bind Therapeutics up big premarket on lead product update and strategic outlook
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 6:50AM CST
BIND: 6.06 (+0.21)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 4:35PM CST
MPW: 14.64 (+0.14), WDFC: 82.95 (+0.21), SU: 31.62 (+0.30), PODD: 32.00 (-0.07), RECN: 17.46 (-0.15), RARE: 54.10 (+0.12), AFSI: 55.60 (-0.89), AGU: 108.58 (+1.60), ALXN: 182.29 (+6.02), BIND: 6.06 (+0.21)
BIND Therapeutics Provides Clinical Update for BIND-014 and 2015 Strategic Overview
Business Wire - Wed Jan 07, 3:00PM CST
--- Initiating Phase 2 clinical trials in a broader array of tumors with a rationale for BIND-014 activity, including cholangiocarcinoma, cervical cancer, bladder cancer and head and neck cancer -
BIND: 6.06 (+0.21)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.83 (+0.22), BIB: 141.30 (+2.39), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), BIND: 6.06 (+0.21), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), ONTY: 1.57 (unch), ECYT: 5.26 (-0.02), BIS: 39.67 (-0.75), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), ARIA: 7.35 (+0.45), IRY: 49.63 (+0.34), IXJ: 104.21 (+0.61), FPRX: 24.63 (+0.63)
BIND Therapeutics to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Wed Nov 26, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference in New York on Thursday, December 11, 2014 at 3:55 p.m. EST.
BIND: 6.06 (+0.21)
